We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+18.92%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$598M
AUM Growth
+$132M
Cap. Flow
+$140M
Cap. Flow %
23.32%
Top 10 Hldgs %
44.39%
Holding
102
New
38
Increased
16
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$24.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$20.2M
3
MSFT icon
Microsoft
MSFT
+$13.9M
4
NTR icon
Nutrien
NTR
+$11.2M
5
AMZN icon
Amazon
AMZN
+$8.28M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.9M
2
ALBO
Albireo Pharma Inc
ALBO
+$10M
3
AZN icon
AstraZeneca
AZN
+$7.74M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$6.51M
5
KROS icon
Keros Therapeutics
KROS
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 59.53%
2 Technology 8.91%
3 Materials 1.8%
4 Consumer Discretionary 1.48%
5 Utilities 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
26
Jasper Therapeutics
JSPR
$21M
$7.32M 1.22%
+404,401
New +$7.48M
PNT
27
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.93M 1.16%
952,642
– –
CAMT icon
28
Camtek
CAMT
$6.18B
$6.79M 1.13%
239,494
+129,494
+118% +$3.45M
SAGE
29
DELISTED
Sage Therapeutics
SAGE
$6.5M 1.09%
+155,000
New +$6.66M
MRUS
30
DELISTED
Merus
MRUS
$6.2M 1.04%
336,993
+20,000
+6% +$348K
SRPT icon
31
Sarepta Therapeutics
SRPT
$1.57B
$6.06M 1.01%
+44,000
New +$5.71M
KZR
32
DELISTED
Kezar Life Sciences
KZR
$5.91M 0.99%
188,823
+58,305
+45% +$3.37M
XLI icon
33
PUT
State Street Industrial Select Sector SPDR ETF
XLI
$32.8B
$5.84M 0.98%
+57,700
New +$5.8M
BLU
34
DELISTED
BELLUS Health Inc.
BLU
$5.76M 0.96%
799,860
+310,000
+63% +$2.4M
PFE icon
35
Pfizer
PFE
$143B
$5.71M 0.95%
+140,000
New +$6.05M
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.63M 0.94%
231,591
+36,000
+18% +$788K
ATXS
37
DELISTED
Astria Therapeutics
ATXS
$5.6M 0.94%
421,018
-48,322
-10% -$653K
NVS icon
38
Novartis
NVS
$297B
$5.52M 0.92%
+60,000
New +$5.24M
IMTX icon
39
Immatics
IMTX
$1.18B
$5.39M 0.9%
780,852
– –
MLYS icon
40
Mineralys Therapeutics
MLYS
$2.25B
$5.31M 0.89%
+339,000
New +$5.71M
ACLX
41
DELISTED
Arcellx
ACLX
$5.16M 0.86%
167,488
-70,000
-29% -$2.12M
PERI icon
42
Perion Network
PERI
$375M
$5.15M 0.86%
+130,000
New +$4.33M
KNSA icon
43
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.85M 0.81%
450,283
+143,000
+47% +$1.88M
FUSN
44
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.84M 0.81%
+1,283,537
New +$5.05M
IRON icon
45
Disc Medicine
IRON
$2.96B
$4.66M 0.78%
+220,013
New +$4.9M
MDGL icon
46
Madrigal Pharmaceuticals
MDGL
$10.8B
$4.6M 0.77%
+19,000
New +$5.18M
GRCL
47
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$4.39M 0.73%
+2,360,580
New +$4.93M
TVTX icon
48
Travere Therapeutics
TVTX
$5.2B
$4.22M 0.7%
+187,500
New +$3.99M
RCKT icon
49
Rocket Pharmaceuticals
RCKT
$340M
$4.04M 0.68%
+236,000
New +$4.62M
PANW icon
50
Palo Alto Networks
PANW
$270B
$3.99M 0.67%
+40,000
New +$3.39M
1
2
3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2023 Portfolio in Review

As of Q1 2023, Sphera Funds Management held 102 positions worth $598M, up 28% from $466M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management deployed $140M of net new capital in Q1 2023, opening 38 new positions and adding to 16 existing holdings. Its largest new stake was Nice: 115,482 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 60% a quarter earlier, followed by Technology and Materials.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $10.9M trimmed.

  • Sphera Funds Management's largest Q1 2023 buy was Nice: 115,482 shares worth $26.4M.
  • Sphera Funds Management added most to Biogen in Q1 2023, an estimated $7.19M increase.
  • Sphera Funds Management's biggest Q1 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.9M.
  • Sphera Funds Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $598M portfolio in Q1 2023.
  • Sphera Funds Management opened 38 new positions and closed 21 in Q1 2023.
  • Sphera Funds Management's portfolio value rose 28% quarter-over-quarter to $598M.

Based on Sphera Funds Management's 13F filing for Q1 2023, filed 15 May 2023.